Journal Mobile Options
Table of Contents
Vol. 22, No. 2, 2003
Issue release date: March–April 2003
Neuroepidemiology 2003;22:146–152

Elevated Suicide Risk among Patients with Multiple Sclerosis in Sweden

Fredrikson S. · Cheng Q. · Jiang G.-X. · Wasserman D.
aDivision of Neurology, NEUROTEC, Karolinska Institutet, Huddinge University Hospital, and bWHO Collaborating Center for Suicide Research and Prevention, National Center for Suicide Research and Prevention of Mental Ill-Health, Department of Public Health, Karolinska Institutet, Stockholm, Sweden

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Results from previous studies of suicide risk among patients with multiple sclerosis (MS) are inconsistent. This may be explained partly by differences in methodology and study populations. The purpose of our study was to investigate suicide risk among hospital patients with MS in Sweden. During the period 1969–1996, 12,834 cases were recorded in the Swedish Hospital Inpatient Register, with 77,377 hospital admissions, in which MS was a primary or secondary diagnosis at discharge. The mean follow-up time for the whole cohort was 9.9 (SD 7.3) years. When the data for these MS patients were linked to the Swedish Causes of Death Register for the same period, 5,052 (39.4%) were found to have died. Among the 5,052 deaths, suicide was an underlying cause of death in 90 cases (1.8%). The mean period between the initial admission date with an MS diagnosis at discharge and the date of death for the 90 MS suicide cases was 5.8 (SD 5.1) years. This was significantly shorter (p = 0.002) than the mean of 7.9 (SD 6.4) years for MS cases who died due to other causes. Suicide risk, calculated as the standardized mortality ratio (SMR), was significantly elevated (SMR = 2.3) among both male and female MS cases compared with the general population. Suicide risk was particularly high in the first year after initial admission with an MS diagnosis, and among younger male MS cases. The mean age at the time of suicide was 44.5 (SD 12.4) years, and 58% of the suicides were committed within 5 years after the first admission with an MS diagnosis. The crude suicide rate among MS patients during the study period was 71 per 100,000 person-years. The rate was significantly higher (p < 0.001) in males (114) than in females (47), with an odds ratio of 2.4 (95% CI: 1.6–3.8). These findings have implications for suicide preventive measures in neurological practice.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Dean G: How many people in the world have multiple sclerosis? Neuroepidemiology 1994;13:1–7.
  2. Rosati G, Aiello I, Pirastru MI, Mannu L, Sanna G, Sau GF, Sotgiu S: Epidemiology of multiple sclerosis in Northwestern Sardinia: Further evidence for higher frequency in Sardinians compared to other Italians. Neuroepidemiology 1996;15:10–19.
  3. Edland A, Nyland H, Riise T, Larsen JP: Epidemiology of multiple sclerosis in the county of Vestfold, eastern Norway: Incidence and prevalence. Acta Neurol Scand 1996;93:104–109.
  4. McDonnell GV, Hawkins SA: An epidemiological study of multiple sclerosis in Northern Ireland. Neurology 1998;50:423–428.
  5. Ford HL, Gerry E, Airey CM, Vail A, Johnson MH, Williams DR: The prevalence of multiple sclerosis in the Leeds Health Authority. J Neurol Neurosurg Psychiatry 1998;64:605–610.
  6. Uria DF, Abad P, Calatayud MT, Virgala P, Diaz A, Chamizo C, Dean G: Multiple sclerosis in Gijon health district, Asturias, northern Spain. Acta Neurol Scand 1997;96:375–379.
  7. Allen IV, Millar JHD, Hutchinson MJ: General disease in 120 necropsy-proven cases of multiple sclerosis. Neuropathol Appl Neurobiol 1978;4:279–284.
  8. Leibowitz U, Kahana E, Jacobson SG, Alter M: The cause of death in multiple sclerosis; in Leibowitz U (ed): Progress in Multiple Sclerosis. New York, Academic Press, 1972, pp 196–209.
  9. Kurtzke JF, Beebe GW, Nagler B, Nefzger MD, Auth TL, Kurland LT: Studies on the natural history of multiple sclerosis. 5. Long-term survival in young men. Arch Neurol 1970;22:215–225.
  10. Sadovnick AD, Eisen K, Ebers GC, Paty DW: Causes of death in patients attending multiple sclerosis clinics. Neurology 1991;41:1193–1196.
  11. Stenager EN, Stenager E, Koch-Henriksen N, Bronum-Hansen H, Hyllested K, Jensen K, Bille-Brahe U: Suicide and multiple sclerosis: An epidemiological investigation. J Neurol Neurosurg Psychiatry 1992;55:542–545.
  12. Stenager EN, Stenager E: Suicide and patients with neurologic diseases. Methodologic problems. Arch Neurol 1992;49:1296–1303.
  13. Gardner MJ, Altman DG (eds): Statistics with Confidence. London, British Medical Journal, 1990.
  14. Gilbert J, Sadler M: Unsuspected multiple sclerosis. Arch Neurol 1983;40:533–536.
  15. Engell T: A clinico-patho-anatomical study of clinically silent multiple sclerosis. Acta Neurol Scand 1989;79:428–430.
  16. Jiang G-X, Cheng Q, Fredrikson S, Link H: First hospital-admission rate as an epidemiological indicator for patients with multiple sclerosis in Stockholm, 1984–1993. Acta Neurol Scand 1999;100:64–68.
  17. Koch-Henriksen N, Bronnum-Hansen H, Hyllested K: Incidence of multiple sclerosis in Denmark 1948–1982: A descriptive nationwide study. Neuroepidemiology 1992;11:1–10.
  18. Larsen JP, Kvaale G, Riise T, Nyland H, Aarli JA: An increase in the incidence of multiple sclerosis in Western Norway. Acta Neurol Scand 1984;69:96–103.
  19. Ahlbom A: Acute myocardial infarction in Stockholm: A medical information system as an epidemiological tool; thesis, Huddinge, 1978.
  20. Allebeck P: Epidemiological investigations on rheumatoid arthritis in Stockholm: The use of different data sources. Scand J Rheumatol Suppl 1984;55:1–29.
  21. Jiang G-X, de Pedro-Cuesta J, Fredrikson S: Guillain-Barré syndrome in South-West Stockholm, 1973–1991. 1. Incidence and quality of registered diagnosis. Acta Neurol Scand 1995;91:109–117.
  22. Sadvonik AD, Remick RA, Allen J, Swartz E, Yee IML, Eisen K, et al: Depression and multiple sclerosis. Neurology 1996;46:628–632.
  23. Guze SB, Robins E: Suicide among primary affective disorders. Br J Psychiatry 1970;117:437–438.
  24. Sainsbury P: Depression, suicide and suicide attempts; in Roy A (ed): Suicide. Baltimore, Williams & Wilkins, 1986, pp 73–88.
  25. Surridge D: An investigation into some psychiatric aspects of multiple sclerosis. Br J Psychiatry 1969;115:749–764.
  26. Baretz RM, Stephenson GR: Emotional responses to multiple sclerosis. Psychosomatics 1981;22:117–127.
  27. Mulder DW: Psychosis with brain tumors and other neurologic disorders; in Arieti S (ed): American Handbook of Psychiatry. New York, Basic Books, 1959.
  28. Honer WG, Hurwitz T, Li DKB, Palmer M, Paty DW: Temporal lobe involvement in multiple sclerosis patients with psychiatric disorders. Arch Neurol 1987;44:187–190.
  29. Dalos NP, Rabins PV, Brooks BR, O’Donnell P: Disease activity and emotional state in multiple sclerosis. Ann Neurol 1983;13:573–577.
  30. Zeldow PB, Pavlou M: Physical disability, life stress, and psychosocial adjustment in multiple sclerosis. J Nerv Ment Dis 1984;172:80–84.
  31. Feinstein A: Multiple sclerosis, depression, and suicide. BMJ 1997;315:691–692.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50